Hangzhou Diagens Biotechnology Co., Ltd. (HKG:2526)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
293.00
+10.80 (3.83%)
At close: Apr 20, 2026

HKG:2526 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023
Period Ending
Dec '25 Dec '24 Dec '23
164.4270.3552.84
Revenue Growth (YoY)
133.72%33.13%-
Cost of Revenue
46.3424.2915.35
Gross Profit
118.0946.0637.5
Selling, General & Admin
84.7450.5751.84
Research & Development
104.3525.5228.64
Other Operating Expenses
-2.071.2
Operating Expenses
196.578.1581.68
Operating Income
-78.41-32.09-44.19
Interest Expense
-0.58-21.19-16.32
Interest & Investment Income
0.831.091.61
Earnings From Equity Investments
0.03-0.1-0
Currency Exchange Gain (Loss)
0.040.060.04
Other Non Operating Income (Expenses)
8.768.662.36
EBT Excluding Unusual Items
-69.34-43.56-56.5
Gain (Loss) on Sale of Investments
--0.19
Gain (Loss) on Sale of Assets
2.20.18-
Other Unusual Items
--0.13
Pretax Income
-67.14-43.39-56.18
Income Tax Expense
0-0.01-0.07
Net Income
-67.14-43.38-56.12
Net Income to Common
-67.14-43.38-56.12
Shares Outstanding (Basic)
807976
Shares Outstanding (Diluted)
807976
Shares Change (YoY)
1.31%3.69%-
EPS (Basic)
-0.84-0.55-0.74
EPS (Diluted)
-0.84-0.55-0.74
Free Cash Flow
--53.98-71.61
Free Cash Flow Per Share
--0.68-0.94
Gross Margin
71.82%65.47%70.95%
Operating Margin
-47.69%-45.62%-83.62%
Profit Margin
-40.83%-61.65%-106.19%
Free Cash Flow Margin
--76.72%-135.52%
EBITDA
-69.11-21.22-39.47
EBITDA Margin
-42.03%-30.16%-74.69%
D&A For EBITDA
9.310.884.72
EBIT
-78.41-32.09-44.19
EBIT Margin
-47.69%-45.62%-83.62%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.